FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224602502> ?p ?o ?g. }

• W4224602502 endingPage "830" @default.
• W4224602502 startingPage "820" @default.
• W4224602502 abstract "Frailty may modify the risk-benefit profile of certain treatments, and frail patients may have reduced tolerance to treatments.To investigate the efficacy of dapagliflozin according to frailty status, using the Rockwood cumulative deficit approach, in DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure).Post hoc analysis of a phase 3 randomized clinical trial. (ClinicalTrials.gov: NCT03036124).410 sites in 20 countries.Patients with symptomatic heart failure (HF) with a left ventricular ejection fraction of 40% or less and elevated natriuretic peptide.Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy.The primary outcome was worsening HF or cardiovascular death.Of the 4744 patients randomly assigned in DAPA-HF, a frailty index (FI) was calculable in 4742. In total, 2392 patients (50.4%) were in FI class 1 (FI ≤0.210; not frail), 1606 (33.9%) in FI class 2 (FI 0.211 to 0.310; more frail), and 744 (15.7%) in FI class 3 (FI ≥0.311; most frail). The median follow-up time was 18.2 months. Dapagliflozin reduced the risk for worsening HF or cardiovascular death, regardless of FI class. The differences in event rate per 100 person-years for dapagliflozin versus placebo from lowest to highest FI class were -3.5 (95% CI, -5.7 to -1.2), -3.6 (CI, -6.6 to -0.5), and -7.9 (CI, -13.9 to -1.9). Consistent benefits were observed for other clinical events and health status, but the absolute reductions were generally larger in the most frail patients. Study drug discontinuation and serious adverse events were not more frequent with dapagliflozin than placebo, regardless of FI class.Enrollment criteria precluded the inclusion of very high-risk patients.Dapagliflozin improved all outcomes examined, regardless of frailty status. However, the absolute reductions were larger in more frail patients.AstraZeneca." @default.
• W4224602502 created "2022-04-27" @default.
• W4224602502 creator A5005006476 @default.
• W4224602502 creator A5007964446 @default.
• W4224602502 creator A5012551917 @default.
• W4224602502 creator A5017272571 @default.
• W4224602502 creator A5018432247 @default.
• W4224602502 creator A5024144703 @default.
• W4224602502 creator A5027213857 @default.
• W4224602502 creator A5030057930 @default.
• W4224602502 creator A5030399648 @default.
• W4224602502 creator A5033436516 @default.
• W4224602502 creator A5034537174 @default.
• W4224602502 creator A5035803645 @default.
• W4224602502 creator A5037009065 @default.
• W4224602502 creator A5047396996 @default.
• W4224602502 creator A5050423418 @default.
• W4224602502 creator A5052533254 @default.
• W4224602502 creator A5054830306 @default.
• W4224602502 creator A5073798303 @default.
• W4224602502 creator A5079993448 @default.
• W4224602502 creator A5080293775 @default.
• W4224602502 creator A5081981822 @default.
• W4224602502 creator A5086692319 @default.
• W4224602502 creator A5090618779 @default.
• W4224602502 date "2022-06-01" @default.
• W4224602502 modified "2023-10-18" @default.
• W4224602502 title "Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction" @default.
• W4224602502 cites W1576645826 @default.
• W4224602502 cites W2035774055 @default.
• W4224602502 cites W2037844081 @default.
• W4224602502 cites W2096061508 @default.
• W4224602502 cites W2105092978 @default.
• W4224602502 cites W2114656311 @default.
• W4224602502 cites W2123048915 @default.
• W4224602502 cites W2129700906 @default.
• W4224602502 cites W2139520621 @default.
• W4224602502 cites W2164059021 @default.
• W4224602502 cites W2336122677 @default.
• W4224602502 cites W2587686068 @default.
• W4224602502 cites W2752401946 @default.
• W4224602502 cites W2754050974 @default.
• W4224602502 cites W2883756867 @default.
• W4224602502 cites W2885596494 @default.
• W4224602502 cites W2889606871 @default.
• W4224602502 cites W2901112941 @default.
• W4224602502 cites W2908418680 @default.
• W4224602502 cites W2910069368 @default.
• W4224602502 cites W2920829402 @default.
• W4224602502 cites W2923389432 @default.
• W4224602502 cites W2957825956 @default.
• W4224602502 cites W2974260792 @default.
• W4224602502 cites W2979434443 @default.
• W4224602502 cites W2981330365 @default.
• W4224602502 cites W2984683166 @default.
• W4224602502 cites W2991340161 @default.
• W4224602502 cites W3000123152 @default.
• W4224602502 cites W3022384237 @default.
• W4224602502 cites W3087129014 @default.
• W4224602502 cites W3102518094 @default.
• W4224602502 cites W3115855235 @default.
• W4224602502 cites W3164577379 @default.
• W4224602502 cites W3193598686 @default.
• W4224602502 doi "https://doi.org/10.7326/m21-4776" @default.
• W4224602502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35467935" @default.
• W4224602502 hasPublicationYear "2022" @default.
• W4224602502 type Work @default.
• W4224602502 citedByCount "39" @default.
• W4224602502 countsByYear W42246025022022 @default.
• W4224602502 countsByYear W42246025022023 @default.
• W4224602502 crossrefType "journal-article" @default.
• W4224602502 hasAuthorship W4224602502A5005006476 @default.
• W4224602502 hasAuthorship W4224602502A5007964446 @default.
• W4224602502 hasAuthorship W4224602502A5012551917 @default.
• W4224602502 hasAuthorship W4224602502A5017272571 @default.
• W4224602502 hasAuthorship W4224602502A5018432247 @default.
• W4224602502 hasAuthorship W4224602502A5024144703 @default.
• W4224602502 hasAuthorship W4224602502A5027213857 @default.
• W4224602502 hasAuthorship W4224602502A5030057930 @default.
• W4224602502 hasAuthorship W4224602502A5030399648 @default.
• W4224602502 hasAuthorship W4224602502A5033436516 @default.
• W4224602502 hasAuthorship W4224602502A5034537174 @default.
• W4224602502 hasAuthorship W4224602502A5035803645 @default.
• W4224602502 hasAuthorship W4224602502A5037009065 @default.
• W4224602502 hasAuthorship W4224602502A5047396996 @default.
• W4224602502 hasAuthorship W4224602502A5050423418 @default.
• W4224602502 hasAuthorship W4224602502A5052533254 @default.
• W4224602502 hasAuthorship W4224602502A5054830306 @default.
• W4224602502 hasAuthorship W4224602502A5073798303 @default.
• W4224602502 hasAuthorship W4224602502A5079993448 @default.
• W4224602502 hasAuthorship W4224602502A5080293775 @default.
• W4224602502 hasAuthorship W4224602502A5081981822 @default.
• W4224602502 hasAuthorship W4224602502A5086692319 @default.
• W4224602502 hasAuthorship W4224602502A5090618779 @default.
• W4224602502 hasConcept C126322002 @default.
• W4224602502 hasConcept C134018914 @default.
• W4224602502 hasConcept C142724271 @default.
• W4224602502 hasConcept C164705383 @default.

• next